Daily Breeze

Bone cancer survivor to urge health advocacy at fundraiser gala in Manhattan Beach

Rosa Cruz is getting used to a new body — and a new life. Cancer shifted the way she communicates with her loved ones, navigates the world and approaches her passions in life. But the 32-year-old San ...
Morningstar

OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor ...

The primary endpoint of 12-month Event Free Survival (EFS) for OST-HER2- treated patients (35%) was statistically significant (p= 0.0194) when compared with peer-reviewed comparable historical control ...
Scientific Research Publishing

Curative Outcome of Osteosarcoma with Associated Pleural Effusion: A Case Report

Dervis, A. (2025) Curative Outcome of Osteosarcoma with Associated Pleural Effusion: A Case Report —Bone Tumor with Pleural ...
Benzinga.com

OS Therapies Reports Strong 2-Year Survival Data For Bone Cancer Immunotherapy Candidate

OS Therapies Inc. (NYSE:OSTX), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, released survival data on Friday from the Phase 2b trial of its off-the-shelf ...
Seeking Alpha

OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

New York, New York--(Newsfile Corp. - October 22, 2025) - OS Therapies Inc. (OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology ...